{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"62","upperLimit":"69","value":"62.5"},{"groupId":"OG002","lowerLimit":"56","upperLimit":"1794","value":"104.0"},{"groupId":"OG003","lowerLimit":"58","upperLimit":"1554","value":"133.0"},{"groupId":"OG004","lowerLimit":"58","upperLimit":"134","value":"96.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"All participants"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"79","upperLimit":"79","value":"79.0"},{"groupId":"OG003","lowerLimit":"69","upperLimit":"1554","value":"1043.0"},{"groupId":"OG004","lowerLimit":"134","upperLimit":"134","value":"134.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"NTDE subpopulation"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"62","upperLimit":"69","value":"62.5"},{"groupId":"OG002","lowerLimit":"56","upperLimit":"1794","value":"105.5"},{"groupId":"OG003","lowerLimit":"58","upperLimit":"1033","value":"96.5"},{"groupId":"OG004","lowerLimit":"58","upperLimit":"58","value":"58.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"TDE subpopulation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"The duration of HI-E response for participants who responded was (the last date of the consecutive hemoglobin \\[Hgb\\] measurements of the first \\>=56 day interval) - (the first date of the consecutive Hgb measurements of the first \\>=56 day interval) + 1 day.","dispersionType":"Full Range","groups":[{"description":"Sotatercept 0.1 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to either the 0.1 mg/kg arm or the 0.3 mg/kg arm. Efficacy and safety data were assessed by a Steering Committee. Based upon the occurrence of dose-limiting toxicity (DLT) in ≤ 1/5 subjects in Cycle 1 in the 0.1 mg/kg and 0.3 mg/kg treatment groups, the 0.5 mg/kg treatment group began inclusion in the randomization scheme.","id":"OG000","title":"Sotatercept 0.1 mg/kg"},{"description":"Sotatercept 0.3 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to either the 0.1 mg/kg arm or the 0.3 mg/kg arm. Efficacy and safety data were assessed by a Steering Committee. Based upon the occurrence of dose-limiting toxicity (DLT) in ≤ 1/5 subjects in Cycle 1 in the 0.1 mg/kg and 0.3 mg/kg treatment groups, the 0.5 mg/kg treatment group began inclusion in the randomization scheme.","id":"OG001","title":"Sotatercept 0.3 mg/kg"},{"description":"Sotatercept 0.5 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to one of the active treatment arms. Efficacy and safety data were assessed by a Steering Committee. Based upon the occurrence of dose-limiting toxicity (DLT) in ≤ 1/6 subjects in Cycle 1 in the 0.5 mg/kg treatment group, the 1.0 mg/kg treatment group began inclusion in the randomization scheme.","id":"OG002","title":"Sotatercept 0.5 mg/kg"},{"description":"Sotatercept 1.0 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to one of the active treatment arms. Efficacy and safety data were assessed by a Steering Committee. Based upon the occurrence of dose-limiting toxicity (DLT) in ≤ 1/6 subjects in Cycle 1 in the 1.0 mg/kg treatment group, the 2.0 mg/kg treatment group began inclusion in the randomization scheme. Following evaluation of all treatment group data by the Steering Committee, enrollment continued only in the 1.0 mg/kg arm because the arm had the greatest frequency of erythroid hematological improvement (HI-E).","id":"OG003","title":"Sotatercept 1.0 mg/kg"},{"description":"Sotatercept 2.0 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to one of the active treatment arms. Efficacy and safety data were assessed by a Steering Committee. The 2.0 mg/kg sotatercept dose was reduced to 1.5 mg/kg for ongoing and newly enrolled participants by protocol amendment.","id":"OG004","title":"Sotatercept 2.0 mg/kg"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Population of participants who responded","reportingStatus":"POSTED","timeFrame":"Day 1 to 183.7 weeks","title":"Duration of Erythroid Hematological Improvement (HI-E)","type":"SECONDARY","unitOfMeasure":"days"}